Upregulation of epidermal growth factor receptor (EGFR) and subsequent increases in extracellular-regulated kinase (ERK) and Akt signaling are implicated in prostate cancer progression. Impaired endocytic downregulation of EGFR also contributes to oncogenic phenotypes such as metastasis. Thus, understanding the roles of divergent signaling pathways in the regulation of EGFR trafficking and EGFRdriven invasive migration may enable the development of more effective therapies. In this study, we use the human prostate cancer cell lines, DU145 and PC3, to investigate the effects of both the ERK and Akt pathways on epidermal growth factor (EGF)-mediated EGFR signaling, trafficking and cell motility. We show that DU145 and PC3 cells overexpress EGFR and migrate in a ligand (EGF)-dependent manner. Next, we show that pharmacological inhibition of ERK (but not Akt) signaling enhances EGFinduced EGFR activation, ubiquitination and downregulation, and may lead to enhanced receptor turnover. These findings negatively correlate with ERK-mediated threonine phosphorylation of EGFR, implicating it as a possible mechanism. Further, we uncover that EGF promotes disassembly of cell-cell junctions, downregulation of E-cadherin and upregulation of the transcriptional repressor, Snail, typical characteristics of epithelial-mesenchymal transition (EMT). These effects are dependent on activation of Akt, as inhibition of Akt signaling abolishes EGF/EGFR-driven cell migration and EMT. Knockdown of endogenous Snail also prevents EGFR-mediated downregulation of E-cadherin, EMT and cell migration. Surprisingly, inhibition of the ERK pathway augments EGFR-dependent motility, occurring concomitantly with elevation of EGF-induced Akt activity. Collectively, our results suggest that EGF-triggered ERK activation has profound feedback on EGFR signaling and trafficking by EGFR threonine phosphorylation, and Akt has a pivotal role in EGFR-mediated cell migration by activating EMT. More important, our results also suggest that therapeutic targeting of ERK signaling may have undesirable outcomes (for example, augmenting EGFR-driven motility).
Introduction
The molecular mechanisms of prostate cancer are still poorly understood, despite the threat that prostate cancer poses to the health of men worldwide. As prostate tumors are initially dependent on androgens for growth and survival, androgen deprivation therapy is commonly the first-line treatment for prostate cancer patients. However, prostate cancer cells can develop a hormonal-refractory (androgen independent) state, rendering principal treatment options palliative because of the acquisition of invasive and metastatic capacities associated with androgen independence. To date, no effective therapy allows the abrogation of prostate cancer's progression to advanced, invasive forms. Recent evidence suggests that acquisition of androgen independence may be due to upregulation of growth factor/receptor signaling pathways, principally the epidermal growth factor receptor (EGFR) (Kambhampati et al., 2005; Traish and Morgentaler, 2009) , making EGFR an attractive target for therapeutic intervention. However, the exact contribution that EGFR makes to prostate cancer progression remains unclear.
EGFR regulates cell growth, differentiation, motility, adhesion and tumorigenesis through interaction with its cognate ligand, epidermal growth factor (EGF). EGFR is the prototype of the ErbB family, which also includes ErbB-2, 3 and 4, and is expressed in nearly all epithelial tissues. EGF engagement activates EGFR's intrinsic kinase and leads to activation of several downstream intracellular signaling pathways, including rat sarcoma-MAPK kinase (MEK)-extracellular-related kinase (ERK) and phosphoinositide 3-kinase (PI3K)-Akt pathways, responsible for a variety of mitogenic, metastatic and other tumor-promoting cellular activities (Wells, 1999; Grant et al., 2002) . On EGF binding, EGFR undergoes a process of internalization, ubiquitination and destruction (known as EGFR endocytosis and trafficking), resulting in temporary EGFR downregulation (Wiley, 2003; Citri and Yarden, 2006) . Impaired endocytic downregulation of EGFR is frequently associated with cancer, as it can lead to uncontrolled signaling and thus to oncogenic phenotypes (Grandal and Madshus, 2008; Roepstorff et al., 2008) . Further data suggest that signaling can also emanate from the EGFR in the process of postendocytic trafficking (Wiley, 2003; Sebastian et al., 2006) . Indeed, we have previously shown that phosphorylation of EGFR at threonine-669 by ERK can influence receptor signaling and trafficking (Huang et al., 2003 (Huang et al., , 2004 (Huang et al., , 2006 Li et al., 2008) . However, the effects that ERKdependent EGFR phosphorylation has on the quantitative and qualitative output from EGFR and cancerous behaviors, such as invasive migration, remain poorly understood. Clinically, upregulation of EGFR and/or ErbB-2 signaling is associated with more aggressive behavior in a broad spectrum of human cancers and correlates with poor prognosis (Yarden and Sliwkowski, 2001; Mendelsohn and Baselga, 2003) . Thus, it is of particular importance to understand the roles of divergent downstream pathways in the regulation of EGFR trafficking and EGFR-mediated cellular processes, as it will enable the development of more effective and selective therapies.
Acquisition of migratory properties is a prerequisite for cancer progression and for invasive migration of tumor cells into surrounding tissue. Within carcinoma (cancer of epithelial origin) cells, acquisition of invasiveness requires a dramatic morphological alteration, termed epithelial-mesenchymal transition (EMT), wherein carcinoma cells lose their epithelial characteristics of cell polarity and cell-cell adhesion and switch to a motile mesenchymal phenotype (Thiery, 2002; Thiery and Sleeman, 2006) . Disruption of cell-cell adherens junctions mediated by E-cadherin (one of the epithelial markers) is considered a crucial step in EMT and downregulation of E-cadherin is common in metastatic carcinomas (Cavallaro and Christofori, 2004) . Reduced E-cadherin expression has been found in high-grade prostate cancers and is associated with poor prognosis (Umbas et al., 1992 (Umbas et al., , 1994 , reflective of its critical role in tumor progression. It is widely believed that downregulation of E-cadherin occurs through transcriptional repression mediated by the protein, Snail (Cano et al., 2000; Peinado et al., 2007; Moreno-Bueno et al., 2008) . Accumulating evidence indicates that the EGFR family and its downstream signaling pathways (for example, PI3K-Akt and rat sarcoma-MEK-ERK) regulate the expression of Snail (Lee et al., 2008; Qiao et al., 2008; Hipp et al., 2010) , suggesting that pharmacological inhibition of these pathways may prevent the loss of E-cadherin function and thereby acquisition of invasive motility.
In this study, we explored the effects of Akt and ERK pathways on EGFR-mediated signaling and motility in human prostate cancer cells. Our novel findings suggest that EGF-triggered ERK activation has profound feedback on EGFR signaling and trafficking by EGFR threonine phosphorylation, whereas Akt has a pivotal role in EGFR-mediated migration. We also present evidence that therapeutic targeting of ERK signaling may have undesirable outcomes (for example, enhancing EGFR-driven prostate cancer cell migration).
Results
DU145 and PC3 cells highly express EGFR, but not ErbB-2, and are responsive to EGF The well-characterized human prostate cancer cell lines, DU145 and PC3, are both androgen insensitive (van Bokhoven et al., 2003) , making them excellent models to study the consequences of EGF-mediated signaling in hormone-refractory prostate cancer. Compared with an androgen-responsive human prostate cancer cell line, LnCap (van Bokhoven et al., 2003) , EGFR proteins were overexpressed in DU145 and PC3, whereas ErbB-2 was mainly expressed in LnCap cells (Supplementary Figure 1a) , indicating that the two androgen-independent cell lines (DU145 and PC3) predominantly expressed EGFR, but not ErbB-2. Phosphorylation of residue 1068 Y is known to correlate with EGFR kinase activation (Rojas et al., 1996) . As shown in Supplementary Figure 1b , EGF induced phosphorylation (activation) of EGFR and activated ERK and Akt in both DU145 and PC3 cells. Notably, Akt was basally activated in PC3 (Supplementary Figure 1b, lane 3) , consistent with a previous report that this cell line harbors PTEN deletion (Davies et al., 2002) . Further, EGF markedly promoted prostate cancer cell migration as measured by wound closure assays (Supplementary Figure 1c) . Collectively, overexpression of EGFR and robust activation of ERK and Akt in response to EGF in DU145 and PC3 cells make these cells appealing systems for evaluating the roles of ERK and Akt pathways in EGFR-mediated actions.
Inhibition of the ERK pathway enhances EGF-induced EGFR activation and downregulation
To understand the functional impact of ERK and Akt inhibition on EGFR activation and trafficking in prostate cancer cells, we used two pharmacological inhibitors, PD98059 and LY294002, to specifically block the MEK-ERK and PI3K-Akt pathway, respectively ( Figure 1b To determine the effects of PD98059 and LY294002 on EGFR trafficking, we compared EGFR protein levels in DU145 cells pretreated with vehicle (dimethyl sulfoxide, DMSO), PD98059 or LY294002 for 1 h, followed by exposure to EGF for 0-30 min (Figure 2a ). In the absence of EGF, neither PD98059 nor LY294002 caused apparent changes in the EGFR mass (data not shown). As expected, EGF treatment alone resulted in a time-dependent loss of EGFR (Figure 2a , upper panel, lanes 2-4). The kinetics was not altered by LY294002 (lanes 8-10 vs lanes 2-4). In contrast, PD98059 led to accelerated ligand-induced EGFR downregulation (lanes 5-7 vs lanes 2-4). Statistical analysis is shown in Figure 2b . Similar results were obtained in PC3 cells (data not shown).
The ERK pathway affects EGFR trafficking by threonine phosphorylation of EGFR Consequent to EGF stimulation, activated EGFR is rapidly ubiquitinated by c-Cbl, an SH2 domain-containing ubiquitin ligase that itself becomes phosphorylated and binds to EGFR, which promotes postinternalization of EGFR and sorting to endosomes and lysosomes for degradation (Levkowitz et al., 1998; Joazeiro et al., 1999; Waterman et al., 1999) . In DU145 cells, EGF stimulation led to EGFR ubiquitination (Figure 3a , upper panel, lane 2), which was enhanced by PD98059 (lane 4 vs 2), but not by LY294002 (lane 6 vs 2). Enhancement of EGFR ubiquitination by PD98059 was statistically significant (Po0.01; Figure 3b ), and correlated with EGFR downregulation (Figure 2 ). We also evaluated the degree of Cbl tyrosine phosphorylation and the level of Cbl proteins associated with EGFR under these conditions (Figures 3c-e) by T by a point mutation (threonine to alanine) resulted in accelerated ligand-induced receptor loss (Li et al., 2008) . To determine whether the effect of PD98059 on EGF-induced activation, ubiquitination (by Cbl) and downregulation of EGFR was related to receptor threonine phosphorylation in prostate cancer cells that endogenously express EGFR, we used a monoclonal antibody (PTP101) that specifically recognizes phosphorylated threonine residues residing within the ERK substrate consensus sites (Huang et al., 2003 (Huang et al., , 2004 (Huang et al., , 2006 Li et al., 2008) . As shown in Figure To confirm that these observations were due to inhibition of ERK and not to an off-target effect of the PD98059 and UO126 compounds, we introduced a constitutively active MEK1 (c.a. MEK1) into DU145 cells and assessed its impact on EGFR. As shown in Supplementary Figure 3 , forced expression of c.a. MEK1 in DU145 cells enhanced EGFR mass and promoted EGFR threonine phosphorylation, when compared with the cells expressing lacZ (control). Our previous work using other cell systems (Huang et al., 2003 (Huang et al., , 2006 Li et al., 2008) suggests that EGF-induced ERK-mediated threonine phosphorylation of EGFR could serve as a brake on EGFR downregulation. Taken together, the current data indicate that inhibition of ERK signaling eliminates EGF-induced EGFR threonine phosphorylation and leads to the release of the 'brake', which in turn enhances receptor activation, ubiquitination (by Cbl) and downregulation. Figure 1c) , we first performed wound closure assays. As shown in Figure 5a , LY294002 markedly inhibited EGF-induced cell migration, compared with vehicle (DMSO). Statistical analysis revealed that LY294002 slowed EGFmediated cell migration by 43% (Po0.01) (Figure 5b) . Surprisingly, PD98059 slightly enhanced the liganddriven migration compared with control (Po0.05; Figure 5b ). Transwell assays confirmed the augmented effects of PD98059 and inhibitory effects of LY294002 on EGF-mediated motility (Figure 5c ). Furthermore, we found that PD98059 boosted EGF-induced Akt activation (Figure 5d , pAkt panel, lane 4 vs 2; lane 10 vs 8) by B23 and 36% in DU145 and PC3 cells, respectively (Po0.01; Figure 5e ), as did UO126 (Supplementary Figure 4) . As a complementary approach to the pharmacological inhibition of the P13K-Akt pathway, we expressed constitutively activated (myristoylated) Akt (Myr-Akt) in DU145 cells and observed a reverse effect (Supplementary Figure 5) , that is, cells expressing Myr-Akt migrated much faster than vector control cells ( Supplementary Figures 5b and c) . In contrast to its inhibitory effect in control cells, LY294002 had no apparent effect on motility in Myr-Akt-expressing cells (Supplementary Figure 5d) , because of the chronic activation of Akt (Supplementary Figure 5a , middle panel, lane 2). Taken together, our data strongly suggest that Akt has a central role in EGF/EGFR-directed prostate cancer cell migration, and augmentation of EGF-induced Akt activity by PD98059 (and UO126) could contribute to enhanced cell motility.
Inhibition of the Akt pathway suppresses EGF-mediated cell migration by blocking Snail upregulation and thereby E-cadherin downregulation
Because of the necessary role of Akt in prostate cancer cell migration, we examined whether EGF-induced activation of Akt promoted EMT-like morphological changes in prostate cancer cells. As shown in Figure 6a , in the absence of EGF, both DU145 and PC3 cells were well organized, tightly packed and formed clustered, cobblestone-like structures, typical of epithelial cells and suggestive of strong cell-cell adhesion. EGF treatment resulted in mesenchymal morphological features, specifically cell shape elongation and scattering, suggestive of reduced cell-cell adherens junctions and increased cell motility. Interestingly, such EGF-induced EMT was markedly diminished when cells were exposed to LY294002, suggesting that activation of Akt is required for EGF-driven EMT.
As downregulation of E-cadherin is a hallmark of EMT, we next assessed the cellular localization and expression levels of E-cadherin in untreated (control) and EGF-treated cells in the presence or absence of LY294002. Immunofluorescent staining showed typical E-cadherin localization at cell-cell junctions in control cells, but such a staining pattern largely disappeared in EGF-treated cells (Figure 6b) , which was consistent with EGF-induced cell morphological changes (Figure 6a Figure 4 EGF-induced EGFR threonine phosphorylation is ERK activation dependent. (a) Serum-starved DU145 cells were pretreated with vehicle (DMSO), PD98059 (50 mM) or LY294002 (50 mM) for 1 h before stimulation with vehicle (-) or EGF (10 ng/ml) for 15 min. Protein extracts were either immunoprecipitated with anti-EGFR, followed by immunoblotting with PTP101 (specifically recognizing phosphorylated threonine residues residing within the ERK substrate consensus sites) or anti-EGFR, or directly immunoblotted with anti-pERK or anti-total ERK, as indicated. (b, c) Serum-starved DU145 cells were pretreated with vehicle (DMSO) or with UO126 (10 mM) for 1 h before stimulation with vehicle (-) or EGF (10 ng/ml) for 15 min. Protein extracts were either immunoprecipitated with anti-EGFR, followed by immunoblotting with PTP101 or anti-EGFR, or directly immunoblotted with anti-pERK, anti-total ERK, anti-phospho-EGFR (pY-1068), anti-EGFR or antib-actin, as indicated.
EGF-treated and untreated cells (Figure 7a , lanes 3 and 4 vs 1 and 2; Figure 7b ). Collectively, these results suggest that EGF-induced activation of Akt drives EMT within prostate cancer cells.
Snail is one of the several transcriptional factors that can suppress E-cadherin gene expression (Batlle et al., 2000; Cano et al., 2000) . Stability of the Snail protein is regulated by GSK3b, a downstream effector of Akt Images were captured at 0 and 9 h after wounding in serum-free media without (control) or with EGF (10 ng/ml) in the presence of vehicle (DMSO), PD98059 (25 mM) or LY294002 (25 mM). Total magnification: Â 100. (b) Percentages of wound closure at 9 h under each condition as in (a) are plotted, in which the wound width was normalized to the initial at 0 h (n ¼ 15 per condition). (c) Transwell assays. PC3 cells were seeded in top chambers that were separated by membranes of 8-mm pore size from lower chambers in serum-free media with or without EGF (10 ng/ml) in the presence of vehicle (DMSO), PD98059 (25 mM) or LY294002 (25 mM). The cells were allowed to migrate for 8 h. The number of cells that migrated across the membranes per imaging field was counted (n ¼ 12 per condition). (d) Inhibition of the ERK pathway boosts EGF-induced Akt activation. Serum-starved cells were pretreated with vehicle (DMSO), PD98059 (50 mM) or LY294002 (50 mM) for 1 h before stimulation with vehicle (-) or EGF (10 ng/ml) for 15 min. Protein extracts were analyzed by immunoblotting with anti-pERK, anti-total ERK, anti-pAkt and anti-total Akt, respectively. (e) Statistical analysis of pooled data, as shown in (d), indicates that the increases of Akt activity by PD98059 are B 23 and 36% in DU145 (n ¼ 4) and PC-3 (n ¼ 3), respectively. Data are mean ± s.e. *Po0.05; **Po0.01.
ERK and Akt in EGFR signaling and cell motility
Y Gan et al (Zhou et al., 2004) . In DU145 cells, EGF induced robust GSK3b phosphorylation (inactivation) and LY294002 markedly inhibited this phosphorylation (Figure 7c To confirm the essential role of Snail in EGF-driven EMT and cell migration, we used small interfering RNAs (siRNAs) to knock down endogenous Snail expression in DU145 cells. Transfection of Snail siRNA (sequence no. 1 or no. 6) into these cells resulted in severe reduction in Snail protein levels (Figures 8a and b) . Compared with nonspecific siRNA (control), knockdown of Snail with siRNA no. 1 significantly prevented the EGF-induced loss of E-cadherin expression ( Figures  8c and d) , and concomitantly suppressed EMT (Figure 8e ), which correlated with a decrease in cell motility (Figure 8f) . However, the EGF-induced phosphorylation of Akt and GSK3b was not attenuated by Snail knockdown (Supplementary Figure 6) . Similar results were obtained when Snail siRNA no. 6 was used (data not shown), ruling out an off-target effect. Inhibition of EGF-induced EMT and cell migration by Snail knockdown was consistent with the effects of LY294002 (compare Figure 8 with Figures 5-7) , suggesting a critical role of Snail in these processes. Taken together, these findings implicate Snail as a central effector of EMT and motility mediated by EGFR-activated Akt within prostate cancer cells.
Discussion
During tumor progression, cancer cells acquire the ability to invade surrounding tissue and metastasize to distant sites, and these malignant properties are reflective of aberrant cell signaling (Martin, 2003) . Overexpression of EGFR and alterations in its downstream signaling pathways, such as rat sarcoma-MEK-ERK and PI3K-Akt, are linked to more aggressive behavior and correlate with poor prognosis of various human malignancies, including prostate cancer (Yarden and Sliwkowski, 2001; Mendelsohn and Baselga, 2003) . However, the exact roles of the ERK and Akt pathways in the regulation of EGFR fate (trafficking) and EGFRdriven cell motility in prostate cancer cells have not been systematically studied yet. On EGF binding, EGFR is activated through phosphorylation at several tyrosine residues located in its cytoplasmic tail, after which EGFR undergoes endocytosis and is targeted for degradation. The ligand-induced downregulation of EGFR is a complex, tightly regulated process, and impaired endocytic downregulation is often associated with malignancy (Grandal and Madshus, 2008; Roepstorff et al., 2008) . Thus, the degree and kinetics of EGFR activity and downregulation are believed to be critical modulators of EGF actions. We previously uncovered that, in addition to tyrosine phosphorylation, EGFR also undergoes threonine phosphorylation in response to EGF, which is ERK activation dependent and can slow the pace of ligand-induced receptor downregulation (Huang et al., 2003 (Huang et al., , 2006 Li et al., 2008) . In this study, we found that blockade of the ERK pathway, but not of the Akt pathway, eliminates EGF-induced EGFR threonine phosphorylation, which in turn potentiates receptor tyrosine phosphorylation (activation) and subsequently enhances EGFR endocytic downregulation in prostate cancer cells. In particular, acceleration in EGF-induced EGFR loss by pharmacological inhibition of the ERK pathway in prostate cancer cells resembles the effects of EGFR T669A mutant ( 669 T was mutated to alanine) in a CHO reconstitution system, in which the EGF-induced downregulation of T669A mutant was much more rapid than that of wild-type EGFR because of loss of phosphorylation at 669 T (Li et al., 2008) . Interestingly, EGF-induced EGFR tyrosine phosphorylation was enhanced in prostate cancer cells treated with MEK1 inhibitors (this study), which is similar to that which we observed previously in the EGFR T669A mutant (Li et al., 2008) . Thus, this study shows a pivotal role of ERK (in contrast to Akt) in the modulation of EGF/EGFR trafficking in a more biologically and pathologically relevant cell system, in which all EGFR signaling elements are expressed endogenously. In addition, we show that forced expression of constitutively active MEK1 (c.a. MEK1), which chronically activates ERK, results in an elevated EGFR expression level (Supplementary Figure 3) . One explanation for this interesting phenomenon is that chronic ERK activation could modulate EGFR trafficking through enhanced EGFR threonine phosphorylation, leading to increased receptor levels. However, we cannot rule out other possibilities, such as direct or indirect regulation of EGFR gene expression by ERK, as overexpression of c.a. MEK1 in any cell type could lead to fundamental changes in cell signaling and behaviors, which warrant further investigation.
Ligand-induced EGFR endocytic downregulation contains multiple steps including sorting to clathrincoated pits, transporting to early endosomes and destining for lysomal degradation or recycling back to the cell surface (Wiley, 2003) . The molecular machinery controlling these processes remains poorly understood. It is believed that ubiquitination has a key role in 'tagging' EGFR for endocytosis. Cbl, a ring-finger domain E3 ubiquitin ligase, is mainly responsible for EGFR ubiquitination (Levkowitz et al., 1998) . One of our novel findings is that inhibition of ERK activity further promotes the association between Cbl and EGFR, which strongly correlates with the augmented ubiquitination of EGFR by PD98059. Emerging evidence suggests that Cbl can bind to EGFR directly at phosphorylated tyrosine residue 1045 (Y1045) or indirectly by adaptor protein Grb2, which binds to phosphorylated EGFR at Y1068 and Y1086 Waterman et al., 2002) . In this study, we show that blockade of the ERK pathway conversely (c) were imaged with total magnification of Â 100. (f) Snail knockdown reduces EGF-driven cell migration. Serum-starved DU145 siRNA transfectants as in (c) were subjected to transwell assay, in which EGF (10 ng/ml) was used as an attractant in the lower chambers. The cells were allowed to migrate for 8 h. The number of cells that migrated across the membranes per imaging field was counted (n ¼ 17 per condition). Data are mean ± s.e. **Po0.01; NS, not statistically significant. enhances the tyrosine phosphorylation of EGFR at multiple sites, including Y1045 and Y1068 (Figure 1c) , presumably by elimination of EGFR threonine phosphorylation (Figure 4 ). This raises several interesting questions, such as through which site(s) or tyrosine residue(s) within the EGFR cytoplasmic tail is the effect of the EGFR threonine phosphorylation exerted; whether Cbl is the sole factor in EGFR ubiquitination or there are any other contributors, such as adaptor proteins Grb2 and/or Eps15 (Waterman et al., 2002; Grandal and Madshus, 2008; Roepstorff et al., 2008) ; and finally whether two completely different types of EGFR phosphorylation (tyrosine vs threonine phosphorylation) exist and how they are balanced under physiological and pathological conditions. Deciphering these mechanisms will require more detailed mutagenesis, in combination with biochemical and cell biological studies in the future. Nevertheless, given the important implications of endocytic downregulation of EGFR in cancer, we are intrigued by the findings herein that the 'on and off' of the ERK pathway markedly influences EGF-induced EGFR trafficking in prostate cancer cells, which are reflected in alterations in receptor activation, ubiquitination and subsequent downregulation.
Another important and intriguing finding from our current study is that pharmacological inhibition of the Akt pathway significantly affects EGF-mediated prostate cancer cell migration, which involves EGF-driven EMT-like morphological changes. The role of EMT in cancer progression has long been appreciated (Thiery, 2002; Moreno-Bueno et al., 2008) . Downregulation of E-cadherin is the key step toward the invasive phase in cancer and E-cadherin gene expression is mainly regulated by the Slug/Snail family of transcriptional repressors that bind to E-box sequences in the proximal E-cadherin promoter (Hemavathy et al., 2000) . Snail is regulated by GSK3b by direct binding and phosphorylation, and inhibition of GSK3b results in upregulation of Snail and downregulation of E-cadherin (Zhou et al., 2004) . This implies that Snail and GSK3b together function as a molecular switch for many signaling pathways leading to EMT, and may provide a new connection of Akt to E-cadherin. Along this line, we uncover that in prostate cancer cells, EGF induces Akt activation, which in turn phosphorylates GSK3b, leads to Snail upregulation and subsequently downregulates E-cadherin. More important, we show that inactivation of Akt largely eliminates these EGF-mediated signaling events, suggesting that Akt is a central player in EGFRdirected cell migration. Similar observations have been recently reported in cervical cancer cells (Lee et al., 2008) . In addition, we found that knockdown of endogenous Snail in prostate cancer cells significantly interrupts EGF-induced E-cadherin loss, EMT and motility. Taken together, our findings that, in prostate cancer cells, EGF-mediated Akt signaling affects both phenotypic and molecular attributes, typical of EMT, provide new insights into the molecular mechanisms of EGFR-driven tumor progression and metastasis.
Although considerable data support a role of receptor tyrosine kinases, including EGFR, in the induction of EMT (Thiery, 2002; Conacci-Sorrell et al., 2003; Lu et al., 2003; Cavallaro and Christofori, 2004; Lo et al., 2007) , there remains little consensus about which downstream pathways are necessary to mediate EGFR-induced EMT. Studies within carcinoma cell lines from disparate epithelial tissues have supplied evidence for several different signaling pathways (b-catenin-TCF/LEF-1, ERK, STAT3), as well as alternate repressors of E-cadherin transcription (Twist, Slug) involved in activation of EMT (Conacci-Sorrell et al., 2003; Lu et al., 2003; Lo et al., 2007) , reflective of the fact that cancer cells can use completely distinct pathways under diverse biological contexts. Our work in prostate cancer cells, in addition to the study in cervical cancer cells (Lee et al., 2008) , adds yet another mechanistic pathway by which carcinoma cells undergo EMT, specifically an EGF/EGFR-mediated EMT pathway through Akt inhibition of GSK3b, followed by stabilization of Snail and downregulation of E-cadherin (EGFR-Akt-GSK3b-Snail-E-cadherin-EMT). Interestingly, we observed that inhibition of ERK signaling rather boosts EGF-induced Akt activation, subsequently enhancing cell motility ( Figure 5 and Supplementary Figure 4) . This phenomenon not only supports the notion that Akt is the key node in EGFRdirected migratory pathways but also boils down to the question of how ERK inactivation affects EGF-induced Akt activity. On the basis of our data, we believe that one mechanism could be through the feedback of ERK on EGFR phosphorylation. One can envision that inhibition of ERK activity eliminates EGFR threonine phosphorylation, resulting in enhanced EGFR tyrosine phosphorylation (activation) and subsequently augmented activation of the downstream PI3K-Akt pathway. The other possibility is that there exists potential crosstalk between ERK and Akt, which is independent of EGFR phosphorylation. If so, one would expect a similar increase in basal (nonligand-induced) Akt activation and cell migration when the ERK pathway is inhibited. However, our results do not favor the latter mechanism, as PD98059 (and UO126) only potentiates ligand-induced Akt activation and cell motility, but not the basal, in our experimental settings ( Figure 5 and Supplementary Figure 4) . Nevertheless, our findings and several other studies (Schlessinger and Hall, 2004; Zhou et al., 2004; Qiao et al., 2008; Wu et al., 2009; Yang and Wolf, 2009 ) highlight that Akt is a critical modulator, when activated by receptor tyrosine kinases (including the EGFR family), in cancer invasion and metastasis, which frequently involves transcriptional repression of E-cadherin by Snail, the key step during EMT.
In summary, in this study, we uncover the distinct roles of EGF-mediated ERK and Akt pathways in the regulation of EGFR signaling, trafficking and cell motility in human prostate cancer cells and provide potential mechanisms that may shed new light on molecular targeting therapeutics. It is of particular importance that inhibition of the ERK pathway can augment EGF-induced Akt activation and cell migration. The latter finding implies that targeting ERK signaling in some cancers (for example, prostate cancer)
